Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Aducanumab In Alzheimer’s A Candidate For Medicare ‘Coverage With Evidence Development’?

Executive Summary

Medicare may look to bolster evidence on Biogen’s potential Alzheimer’s treatment, if approved, with a national coverage decision requiring the collection of clinical data in the postmarket setting.

You may also be interested in...



All Alzheimer’s Eyes On Medicare: CMS Will Take The Lead On Tailoring Access To Aduhelm

Biogen/Eisai’s newly-approved Alzheimer’s drug could be headed to CMS’ Medicare advisory committee, which is chaired by vocal drug pricing reform advocate Peter Bach.

With Aduhelm Out Of The Gate, Biogen Focuses On Clearing Commercial Bottlenecks

PET scans and CSF testing to confirm the presence of amyloid beta, and reimbursement, are expected to be early hurdles for launching aducanumab in Alzheimer's.

Patient Support May Have Helped Push Aduhelm Toward Approval

After largely negative advisory committee meeting, a patient group held a listening session with the FDA to be sure their voices were heard during the review of Biogen's aducanumab.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel